MYH14 and COVID-19: Similarly, patients who develop vascular and myocardial autoimmunity following COVID-19 are characterized by displaying antibodies that cross-react with cardiac cardiolipin (CL), alpha and beta adrenergic receptors, as well as myosin and collagen [132,133].